Kornimate/medical-research-clean huggingface dataset:
efficacy of glycine powder air-polishing combined with scaling and root planing in the treatment of periodontitis and halitosis

Conditions: Halitosis

Summary: the aim of this clinical study was to evaluate the clinical efficacy of using perio flow adjunctively with mechanical instrumentation on periodontal parameters and halitosis. sixty patients who presented with 4-6-mm probing pocket depth (ppd) were recruited for the study. patients were randomly assigned to glycine powder air-polishing (gpap) or control groups. for both groups ppdscores were recorded at the baseline and 1 month. volatile sulphur compound (vsc) values were measured by a halimeter at the baseline, immediately after treatment, and at 7 days, 14 days and 1 month.


Eligibility criteria:
inclusion criteria: * in the present trial, patients who had at least three teeth with 4-6-mm periodontal pockets. exclusion criteria: * acute infectious oral lesions, * furcation defects, * using antibiotics for any reason in the last 4 weeks, * periodontal treatment in the last 6 months and * pregnant or lactating patients.

Keywords: air polishing
registry of the evolution of diagnosed and/or hospitalized patients for pulmonary embolism during the covid-19 pandemic

Conditions: Pulmonary Embolism

Summary: the purpose of the study covid-ep is to classify all the complications occurring after the diagnosis of pulmonary embolism in patients tested initially covid-19 positive and negative by rt-pcr (on nasopharyngeal sample) during the peak of the pandemic in france (april 2020). the patients will be followed for 1 year in order to provide clinical and paraclinical data not yet published in the literature. in order to secondarily confirm the covid-19 status of initially negative covid-19 patients (by rt-pcr), a serology test will be performed. the collected complications will then be compared between each of the 3 following groups: \[pcr-covid 19-neg \& sero-covid 19-neg\] versus \[pcr-covid 19-neg \& sero-covid 19-pos\] versus \[pcr-covid 19-pos\].


Eligibility criteria:
inclusion criteria: * aged ≥ 18 years, * diagnosed for pulmonary embolism between april 1st and april 30th, 2020; (treated by ambulatory care or hospitalized), * having given free and informed written consent, * being affiliated with or benefiting from a social security scheme. exclusion criteria: * subject to a measure for the protection of justice.
grid laser for diffuse diabetic maculopathy

Conditions: Diabetic Macular Edema

Summary: diabetic related complications are increasing day by day due to increse in the number of diabetic patients all over the world. diabetic macular edema is one of them and a major cause of vision imparment. various kind of treatment modalities are preent to treat this coplication. grid laser is one treatment modality. laser phtocoagulation is a destrictive procedure.laser power if kept to aminimum can get the desired results without severe destruction to the retina . in this study, the investigators are going to document the effect of minimal grid laser tn loss o overcome the visioe to diabetic macular edema.


Eligibility criteria:
inclusion criteria: * diabetic patients with macular edema. * both sexes * conset to participate. exclusion criteria: * focal edema. * patients requiring only the focal laser. * patients with proferative diabetic retinopathy. * patients with ischaemic maculopathy on fundus fluorescein angiography.

Keywords: macular grid subthreshold diabetic macular edema decrease in visual acuity
effect of add-on citalopram to risperidone on negative symptoms in schizophrenia

Conditions: Schizophrenia; Negative Symptoms

Summary: negative symptoms in schizophrenia present a challenge to the clinician owing to their poorer response to conventional treatment with antipsychotics. negative symptoms in schizophrenia may be secondary to psychotic symptoms, depressive symptoms, drug-related side effects or lack of environmental stimulation. alternately, they may represent core features of the illness, characterized as primary deficit symptoms. previous studies have suggested that atypical antipsychotics may be beneficial in improving deficit symptoms of schizophrenia. this study aimed at characterizing the nature of improvement of negative symptoms in the early phase (12 weeks) of treatment with the atypical antipsychotic, risperidone. in order to account for factors contributing to improvement in secondary negative symptoms, ratings were carried out of change in positive symptoms, depressive symptoms and drug-related side effects. further, add-on citalopram or placebo were administered in a double-blind design to study the effect of selective serotonin reuptake inhibitor (ssri) augmentation of risperidone on negative symptoms. the investigators hypothesized that the improvement in negative symptoms during the initial phase (12 weeks) of treatment with risperidone will be largely accounted for by improvement in secondary negative symptoms, rather than of the primary deficit symptoms.


Eligibility criteria:
inclusion criteria: * patients fulfilling dsmiv criteria for schizophrenia * the patient should be drug naïve or drug free for one month (oral antipsychotic) or three months of parental antipsychotic * duration from onset \< 5 years * informed consent exclusion criteria: * patient with any other current axis i or axis ii comorbid disorders * comorbid substance abuse or dependence except nicotine or caffeine * presence of significant medical disorder such as epilepsy, uncontrolled hypertension and diabetes mellitus, thyroid disorder * patient who has not responded to adequate course of risperidone (with reference to dose and duration) * treatment-resistant schizophrenia defined as non-response to three different antipsychotics belonging to at least two different classes, one of which is an atypical agent and one of which is a depot neuroleptic * patient who has received ect in past 3 months

Keywords: schizophrenia risperidone citalopram secondary negative symptoms
computer modeling with reconstruction of maxillofacial skeleton

Conditions: Maxillofacial Injury

Summary: investigator initial study to evaluate the use of preoperative computer modeling and the intraoperative navigation to guide reconstruction of the maxillofacial skeleton.

the concept of open reduction and internal fixation of facial fractures is well accepted. however, there are situations in which an accurate reduction and restoration of facial symmetry is challenging. in these more difficult cases, the pi uses computer aided design/modeling software as well as intra-operative computer aided surgical navigation systems to assist with repair of these complex injuries. a retrospective review of these cases has not previously been performed.

Eligibility criteria:
inclusion criteria: * specific complex maxillofacial trauma exclusion criteria: * must meet inclusion criteria

Keywords: computer aided design maxillofacial fracture orbital design
visual perceptual learning for the treatment of visual field defect

Conditions: Stroke; Visual Field Defect

Summary: this study will test the hypothesis whether visual field defect caused by chronic stroke could be improved by visual perceptual learning. the secondary hypothesis is that improvement of visual field defect would be accompanied by connectivity changes in visual networks. in addition, investigators will evaluate whether improvement of visual field defect could achieve improvement of subjective visual function.

study design: a probe (prospective, randomized, open-label, blinded-endpoint) design methods: 1. visual perceptual learning (vpl) group 1. visual perceptual learning (24 times for 2 months, 3 times per week) in visual field defect areas 2. at baseline and post-vpl evaluations (2 months after): structural \& functional mris, visual field tests, visual evoked potential, visual cognitive tests, subjective visual function questionnaires 2. control group 1. at baseline and 2-months later: no vpl, structural \& functional mris, visual field tests, visual evoked potential, visual cognitive tests, subjective visual function questionnaires 2. visual perceptual learning after 2-month follow-up evaluation (24 times for 2 months, 3 times per week) (the patients who were stratified by age (over 65 years old or not) and degree of visual field defect (quadrantanopia or complete hemianopia) will be randomly assigned into the learning and control group.) 3. investigations 1. improvement of visual field test scores between vpl group and control group 2. analysis of brain network changes in mri data 3. correlation analysis of improvement of visual field defect and mri data 4. correlation analysis of improvement of visual field defect and visual evoked potential (vep) data 5. correlation analysis of improvement of visual field defect and neuropsychological data

Eligibility criteria:
inclusion criteria: 1. the patient has chronic stroke more than 6 months after onset. 2. the patient has visual field defect (quadrantanopia or hemianopia). 3. the patient has corrected eyesight 0.7 or above. exclusion criteria: 1. the patient has contraindication to mri scan. 2. the patient has cognitive impairment (mini-mental status exam score \<24). 3. the patient has ophthalmologic diseases (e.g., glaucoma, cataract).

Keywords: stroke visual field defect visual perceptual learning brain connectivity
ripasudil for enhanced corneal clearing following descemet membrane endothelial keratoplasty in fuchs' dystrophy

Conditions: Fuchs Endothelial Dystrophy

Summary: recently, published literature has reported that performing a descemetorhexis in combination with topical rho kinase (rock) inhibitor therapy was successful in clearing edematous corneas in patients with fuchs endothelial corneal dystrophy. ripasudil hydrochloride hydrate( glanatec ophthalmic solution 0.4%), a potent rock inhibitor, has been approved in japan since 2014 for ocular use in the treatment of glaucoma. ripasudil acts as an iop-lowering drug by affecting aqueous outflow through the trabecular meshwork and schlemm's canal. the goal of this study is to test the potential benefits of ripasudil therapy administered after descemet membrane endothelial keratoplasty (dmek) surgery. we believe that performing a standard dmek surgery in combination with ripasudil treatment in patients with fuchs endothelial corneal dystrophy could accelerate endothelial cell healing and clear edematous corneas faster, with less post-operative complications.


Eligibility criteria:
inclusion criteria: * diagnosed clinically with fuchs endothelial corneal dystrophy by the study investigator. * phakic or pseudophakic with posterior capsule supported, suture-fixated, or sulcus-supported posterior chamber intraocular lens. * fuchs dystrophy grades 2-5 on the krachmer grading scale. * presence of central guttae and/or stromal edema being the primary cause of decreased vision. * the peripheral cornea to the central 6mm is devoid of guttata changes. * best corrected visual acuity in the study eye is 20/40 or worse with glare testing at study enrollment. exclusion criteria: * uncontrolled glaucoma (iop \>25 mmhg). * presence of secondary corneal pathology such as infective or autoimmune keratitis. * advanced corneal stromal edema with bullae on slit-lamp biomicroscopy. * history of herpes simplex virus or cytomegalovirus keratitis. * prior penetrating keratoplasty. * aphakic in study eye. * allergy to any component of the ripasudil hydrochloride hydrate 0.4% that will be used in the course of the study. * tubes or trabeculectomy from prior glaucoma surgery.
prognostic factors following ankle fractures

Conditions: Ankle Fractures

Summary: ankel fractures is a common fracture. most patients experience that the regain normal range of motions and limited pain within the first 6 months following ankel fracture, but not all. the aim of the study is to determine if any prognostic factors is associated with a worse outcome.

aim of study: to identify prognostic factors associated with a worse outcome following ankle fractures. method: all operated or non-operated ankle fractures in a period of one year from three different hospitals will be included. the following data will be recorded: civil registration number, age, rupture of the syndesmosis, use of alcohol, smoking, diabetes, characteristics of the ankle fracture (ao classification), type of treatment and complications. study participants will at time of diagnosis and 6, 12, 52 and 104 weeks following the injury received a questionaire with manchester foot and ankle questionnaire (moxfq), self-reported foot and ankle questionnaire (sefas), olerud molander ankle score (omas) and forgotten joint score (fjs). which of the questionaire that should be used in the study will be determined when the questionaires have been compared in a different study.

Eligibility criteria:
inclusion criteria: * all patients with ankle fracture. exclusion criteria: * age below 18 years * patients who do not speak or understand danish * mental disable patients
macce after endoscopic vein harvest for cabg

Conditions: Complications Due to Coronary Artery Bypass Graft

Summary: most patients undergoing coronary artery bypass grafting (cabg) will require long saphenous vein (lsv) harvesting from the leg. this has been reported to be associated with a significant morbidity (leg swelling, pain, infection, bruising, wound discharge) in up to 50% of patients. endoscopic vein harvesting (evh) which has been reported to be associated with a reduction in these complications was implemented within the investigators' service in 2012. although some initial reports of concerns regarding graft patency when the lsv is harvested by evh, nice and european cardiology society (esc/eacts) guidelines 2014 supported the use of the evh technology. last year a service evaluation in the investigators' department showed significant cost benefit of evh as compared to open vein harvest (ovh) in a matched group (50 evh and 50 ovh patients). the purpose of this study is to evaluate this group further to assess the incidence of macce (major adverse cardiac and cerebrovascular event) and patient's quality of life (qol) at least 1 year after their surgery. macce will be assessed by contacting the patient's gp and/or cardiologist and qol questionnaire (sf12v2) will be sent to patients along with a patient information sheet. it is estimated that data collection would be completed within 3 months of start.


Eligibility criteria:
inclusion criteria: 1. patient underwent cabg (isolated or combined) during period jan 2012 to dec 2013 2. lsv harvested by evh (study group) 3. lsv harvested by ovh matched with evh group (control group) exclusion criteria: 1. patient deceased at time of study start
effect of adiposity on hepatic and peripheral insulin resistance in type 1 diabetes

Conditions: Type1 Diabetes Mellitus; Adiposity

Summary: the purpose of this study is to assess the effects of adiposity on resistance to insulin's ability to suppress hepatic glucose production and to stimulate peripheral glucose metabolism in adolescents with type 1 diabetes. in addition, this study will also examine the role of fatty liver disease on the insulin resistance of obesity in adolescents with type 1 diabetes.

a major focus of this program of research will be directed at advancing the understanding of the metabolic consequences of obesity and puberty in adolescents with t1d. thus, an innovative aspect of this research is that it will be the first to use these sophisticated metabolic techniques to examine the effects of obesity and hepatic steatosis on insulin sensitivity in pubertal adolescents with t1d; namely, the 2-step hyperinsulinemic euglycemic clamp with tracer enhancement, which will allow for definition of hepatic and peripheral insulin resistance, glycerol turnover, and glucose and fat oxidation. further, a second novel aspect is that this will be the first study to utilize gold standard mri methods to quantify and compare intrahepatic fat content in lean and obese adolescents with t1d. this will allow a global and more detailed understanding of the potential alterations of insulin's effects on key insulin sensitive tissues in youth that are impacted by both t1d and obesity. furthermore, evaluation of biomarkers for insulin resistance and fatty liver disease in this population will be performed for the first time.

Eligibility criteria:
inclusion criteria: * all participants: 1. clinical diagnosis of t1d 2. hba1c ≤9% 3. diabetes duration of at least 12 months adolescents with t1d: 1. age 12-16 years 2. bmi \ 85th percentile for overweight/obese pediatric subjects; 3. tanner stage 2-5 4. parent able to provide written consent and participant able to provide assent 5. not meeting mri safety criteria 6. claustrophobia that will prevent participation in the mri lean, young adults with t1d: 1. age 18-24 years 2. bmi 18.5-24.9 kg/m2 3. able to provide written consent. exclusion criteria: 1. use of adjunctive diabetes medications 2. weight loss medications within the past six months 3. current psychiatric disorders, including eating disorders (dsm-v criteria) 4. known liver disease other than nonalcoholic hepatic steatosis 5. females who are pregnant or lactating 6. anemia or another medical condition that precludes participation in the study
evaluation of different analysis methods for circulating tumor cells, circulating endothelial cell, and circulating tumor dna in patient followed for a tumoral pathology

Conditions: Solid Tumor.

Summary: fifteen cohorts will be opened. each cohort will explore one analysis method and/or tumoral type. up to 50 patient can be included into each cohort.


Eligibility criteria:
inclusion criteria: * 18 years old or more * performance status from 0 to 4 * patient treated followed for histologically confirmed solid tumor type of any of these localization : breast, prostate, uterus, ovary, colon, lung, head and neck, melanoma. * informed consent form signed. exclusion criteria: * patient with history of other invasive cancer within 5 years. * patient treated for any non-invasive cancer * patient individually deprived of liberty or placed under the authority of a tutor * geographical condition potentially preventing compliance with the study protocol.
radiofrequency ablation of lung tumors

Conditions: Lung Cancer; Metastasis

Summary: radiofrequency ablation has achieved impressive results in the treatment of unresectable primary and metastatic liver cancer. animal studies have demonstrated that radiofrequency can fully ablate lung tumors in animal models. we set up a prospective study to evaluate the local efficacy of radiofrequency ablation of lung neoplasms. the aim of the study is to prospectively evaluate local efficacy with a minimal follow-up of one year, tolerance, lung disease-free survival and survival after radiofrequency ablation of lung tumors (primary lung cancer or lung metastases).

radiofrequency (rf) ablation has achieved impressive results in the treatment of unresectable primary and metastatic liver cancer. animal studies have demonstrated that rf can fully ablate lung tumors in animal models. we set up a prospective study to evaluate the local efficacy of radiofrequency ablation of lung neoplasms with a minimal follow-up of one year. the primary endpoint was to determine the rate of incomplete local treatment at 1 year. the secondary endpoints were to evaluate tolerance, survival, disease-free survival and lung tumor-free survival. patients are followed-up by ct scan examination at day 1 or 2 before discharge from the hospital, then at 2, 4, 6, 9 and 12 months and then at 2 years

Eligibility criteria:
inclusion criteria: * unilateral or bilateral unresectable primary or metastatic lung tumors \<= 40 mm and a number of tumor \<=5 * tumors located more than 1 cm from the hilum, and not involving soft tissues or mediastinum. * malignancy histologically proven for pulmonary nodules in patients with no history of cancer outside the lung. * lung tumors in patients with a known distant cancer history, has to be either histologically proven or a demonstrated change in size of at least 25% in their largest diameter is required on ct during the previous year * pretreatment imaging work-up within 4 weeks of scheduled rf ablation (at least a chest ct and an abdomino-pelvic ct) * if a tumor is found outside the lung, it has to be amenable to complete eradication with rf or rf plus surgery * lung spirometry within 4 weeks of treatment with a fev1 \>= 1 liter * written informed consent. exclusion criteria: * uncorrectable coagulopathy with a prothrombin time greater than 1.5 and a platelet count below 106/mm3

Keywords: lung metastasis lung cancer radiofrequency ablation
sintilimab and linperlisib combination treatment in relapsed or refractory extranodal natural killer/t cell lymphoma

Conditions: Extranodal Natural Killer/T Cell Lymphoma

Summary: this is an open-label, phase ib study evaluating the combination treatment of sintilimab and linperlisib in patients with relapsed or refractory extranodal natural killer/t-cell lymphoma (nktcl).


Eligibility criteria:
key inclusion criteria: 1. pathologically confirmed extranodal nktcl. 2. voluntary participation in the clinical study; fully understand the study, and have signed the written informed consent form. 3. age ≥ 18 years. 4. relapsed or refractory nktcl after failure of at least one line of asparaginase-based chemotherapy or chemoradiotherapy regimen. 5. ecog performance status: 0-2. 6. estimated survival time ≥ 3 months. 7. at least one measurable lesion according to the lugano 2014 lymphoma evaluation criteria. 8. adequate organ and bone marrow function. key exclusion criteria: 1. patients previously treated with pi3k inhibitors. 2. patients with hemophagocytic syndrome. 3. patients known to be allergic to any component of monoclonal antibodies. 4. patients with a history of other malignancies within the past 5 years or concurrent malignancies (excluding basal cell carcinoma of the skin). 5. patients with aggressive nk-cell leukemia or central nervous system involvement. 6. patients who have participated in other drug clinical trials within 4 weeks prior to the start of this study or have received anti-tumor treatment within 4 weeks before the study initiation. 7. patients with clinically significant gastrointestinal abnormalities that may affect drug intake, transport, or absorption (e.g., inability to swallow, chronic diarrhea, intestinal obstruction) or patients who have undergone total gastrectomy. 8. patients with a history of interstitial lung disease (except for asymptomatic interstitial lung disease caused by radiotherapy).

Keywords: sintilimab linperlisib extranodal natural killer/t cell lymphoma